Science magazine recaps issues discussed at AIDS 2012

NewsGuard 100/100 Score

Science looks back at the XIX International AIDS Conference (AIDS 2012), which ended last week in Washington, D.C., writing, "The battle against HIV is having more success than ever. ... But several presentations made clear that a gulf separates aspirations from reality when it comes to 'ending AIDS,' which [Secretary of State Hillary] Clinton and many other prominent speakers at the conference emphasized was now possible." Though more people are on antiretrovirals (ARVs) now than ever, low- and middle-income countries are spending more on HIV/AIDS, and "attempts to find a cure -- long viewed as a fantasy -- now lead the scientific agenda," most "of the 34 million HIV-infected people in the world do not take ARVs, many receiving treatment have trouble staying on the medication, ... new infection rates continue to climb in key populations," "[n]o AIDS vaccine is on the horizon," and "funding shortfalls loom for global programs," Science writes, quoting several speakers at the conference and providing more detail on the successes and challenges in the response against HIV/AIDS (Cohen, 8/3).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Closing the Cancer Care Gap with the Power of Precision Oncology